Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Other Accumulated Expenses (2021 - 2025)

Kiniksa Pharmaceuticals International (KNSA) has disclosed Other Accumulated Expenses for 5 consecutive years, with $22.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Other Accumulated Expenses rose 29.85% year-over-year to $22.1 million, compared with a TTM value of $22.1 million through Dec 2025, up 29.85%, and an annual FY2025 reading of $22.1 million, up 29.85% over the prior year.
  • Other Accumulated Expenses was $22.1 million for Q4 2025 at Kiniksa Pharmaceuticals International, up from $628000.0 in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $22.1 million in Q4 2025 and bottomed at $250000.0 in Q2 2023.
  • Average Other Accumulated Expenses over 5 years is $8.3 million, with a median of $8.1 million recorded in 2022.
  • The sharpest move saw Other Accumulated Expenses plummeted 96.76% in 2023, then soared 4873.33% in 2024.
  • Year by year, Other Accumulated Expenses stood at $370000.0 in 2021, then surged by 2164.32% to $8.4 million in 2022, then fell by 5.77% to $7.9 million in 2023, then skyrocketed by 115.91% to $17.0 million in 2024, then grew by 29.85% to $22.1 million in 2025.
  • Business Quant data shows Other Accumulated Expenses for KNSA at $22.1 million in Q4 2025, $628000.0 in Q3 2025, and $18.0 million in Q2 2025.